Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial

Progress in Neuro-psychopharmacology & Biological Psychiatry
Hitoshi TakahashiHisashi Higuchi

Abstract

The purpose of this study was to assess the effect of switching to risperidone in the treatment of first-episode schizophrenia who had failed to respond to an initial-prescribed antipsychotic, olanzapine. Fifty-one patients with first-episode schizophrenia after unsuccessful treatment of olanzapine (the mean (S.D.) dosage: 16.4 (4.4) mg/day) were included in this switching study. Of the 51 patients, 43 (84.3%) completed the full 12-week trial and 8 (15.7%) dropped out. The mean dosage of risperidone at the endpoint (last observation) was 3.1 (2.0) mg/day. The total scores of Brief Psychiatric Rating Scales (BPRS) were significantly reduced from baseline to endpoint, especially in the positive and excitement factors (p<0.001). Responder rate (at least 20% decrease in BPRS total score plus final Clinical Global Impression score of 3 or less) was 35.3%. These findings indicate that the switching to risperidone could be one of the useful treatment options in this population.

References

Jan 1, 1995·Psychopathology·J P LindenmayerN Bark
Jul 31, 2001·Journal of Clinical Psychopharmacology·J P LindenmayerA Iskander
Nov 6, 2002·The Journal of Clinical Psychiatry·Jean-Pierre LindenmayerJoseph P McEvoy
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Julio BobesMiguel Gutiérrez
May 27, 2003·Schizophrenia Research·S Charles SchulzMartin Brecher
May 3, 2005·The American Journal of Psychiatry·Rikus KnegteringRobert J van den Bosch
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Jul 12, 2005·Schizophrenia Bulletin·Ashok Malla, Jennifer Payne

❮ Previous
Next ❯

Citations

Sep 22, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ion-George AnghelescuMark E Schmidt
May 28, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ofer AgidGary Remington
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Apr 10, 2014·Evidence-based Mental Health·Markus Dold, Stefan Leucht
Apr 10, 2008·Current Medical Research and Opinion·Douglas E FariesBruce J Kinon
Nov 26, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Daeyoung RohChan-Hyung Kim
Jun 4, 2015·Psychiatry and Clinical Neurosciences·Kotaro Hatta
May 23, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Kotaro Hatta, Hiroto Ito
Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk
Oct 17, 2018·NPJ Schizophrenia·Richard NewtonBenedicto Crespo-Facorro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved